Durata Therapeutics enters into an exclusive license and supply agreement with Angelini
Durata Therapeutics announced that its Dutch subsidiary, Durata Therapeutics International, has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries. July 30, 2014